Technological Advancements in Structural Heart Devices Industry Research Report Forecasts 2018-2022 Structural Heart Devices Market Report, published by Allied Market Research, forecasts that the global market was valued at $6,006 million in 2015, and is expected to reach $12,076 million by 2022, supported by a CAGR of 10.5% during the forecast 2022. The structural heart repair devices segment held nearly half of the total market share in 2015, and is expected to dominate during the forecast period. Rise in incidence of aortic stenosis, introduction of technologically advanced products (such as the Trifecta valve with Glide Technology), and increase in awareness about the benefits and availability of structural heart devices worldwide are major factors that drive the market growth. In addition, increase in number of application areas for repair and replacement devices coupled with its rise in adoption of annuloplasty rings and tissue valves is expected to further fuel this growth. However, stringent approval process and high cost of surgeries restrict the market growth. Tissue heart valves is expected to maintain its dominant position throughout the analysis period, due to its significant property of low requirement of anticoagulants, which reduces incidence of bleeding and thereby lowers the usage of anticoagulant by the patient. The occluders segment accounted for two-fifths of the overall structural heart repair devices market in 2015, owing to its benefits in the treatment of congenital heart diseases and high adoption rate. In addition, annuloplasty ring is projected to register the highest CAGR of 13.3% during the forecast period.
Complete FREE PDF Report Click Here: https://www.alliedmarketresearch.com/request-sample/1768
Segment review
According to AMR analysis, the structural heart repair devices segment held nearly half of the global structural heart devices market size in 2015, owing to increase in prevalence of structural heart diseases. In addition, advancements in repair devices and development of innovative products have further fueled the market growth.
LAMEA structural heart devices industry
Rise in incidence of aortic stenosis coupled with rapid adoption of structural heart devices drives the growth of the structural heart devices market in LAMEA. In addition, increased focus of structural heart devices vendors in emerging markets (such as Asia-Pacific and LAMEA) is set to further contribute to the growth of this market. Lack of healthcare facilities and increased need for treatment devices for structural heart diseases have increased the penetration of major players in the Middle East. Nevertheless, the structural heart devices market growth is driven by improving healthcare infrastructure coupled with rise in disposable income.
Top impacting factors Rise in number of patients suffering from structural heart diseases
An increase in demand for structural heart devices has been witnessed, owing to the rise in number of patients suffering from structural heart diseases. These disorders are generally congenital; hence, they occur very commonly in a newborn. For instance, as per The Nemours Foundation, about 1 in every 100 newborns suffers from congenital heart defects, which can range from mild to severe. According to Micro Interventional Devices, Inc., in the U.S., about 60 million people, i.e., about 20-25% adult population suffer from structural heart defects. As per the Center for Structural Heart Disease at Henry Ford Hospital (CSHD), in Henry Ford Hospital, about 250,000 patients are diagnosed with mitral valve diseases annually. Moreover, in Europe, the prevalence of aortic stenosis is 1.75 million. These statistics clearly highlight the need for structural heart treatment devices, thus providing impetus to develop new techniques for repair and replacement of heart defects. In 2007, TAVR procedures were approved in Europe and in 2012 in the U.S. Moreover, around 80,000 patients undergo mitral valve repair or valve replacement surgery each year. Technological advancements in structural heart devices industry The upgraded treatments for improving quality of life and increased life expectancy fuel the demand for technologically advanced structural heart devices, such as advanced tissue heart valves useful in structural heart repair and replacement. Further, with the advent of tissue valves used in tissue aortic valve replacement, the quality of life for patients suffering from aortic regurgitation has improved. For instance, in April 2016, launch of St. Jude’s Trifecta valve with Glide Technology (GT), an advanced tissue valve, has made options available for patients in need of aortic valve replacement. Technological innovations result in change in heart-related disorder treatment patterns, lowering the burden of heart disease. Novel tissue valves and mechanical heart valves are widely used to treat structural heart defects with greater longevity. STRUCTURAL HEART DEVICES MARKET KEY BENEFITS: •
The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
•
It offers a quantitative analysis from 2014 to 2022 to enable stakeholders to capitalize on the prevailing market opportunities.
•
Extensive analysis of the market based on products helps to understand the type of devices used to treat structural heart diseases.
•
Competitive intelligence highlights the business practices followed by leading players across various regions.
•
Comprehensive analysis of all geographical regions helps to determine the prevailing opportunities.
•
Key players and their strategies are analyzed to understand the competitive outlook of the overall market.
•
Extensive analysis is conducted by following key product positioning and monitoring the top contenders within the market framework.
•
STRUCTURAL HEART DEVICES MARKET KEY SEGMENTS
By Product •
Repair Devices o
Annuloplasty Rings
o
Heart Valve Balloons
o
Occluders
•
Replacement Valves o
Mechanical Heart Valves
o
Tissue Heart Valves
By Indication •
Atrial Septal Defect (ASD)
•
Ventricular Septal Defect (VSD)
•
Patent Foramen Ovale (PFO)
•
Aortic Valve Stenosis
•
Others
By Age Group •
•
Pediatric o
Infants (6 months to 12 months)
o
Toddlers (1-2 years)
o
New Born (0-5 months)
o
Preschooler (3-5 years)
o
School-aged Children (6-12 years)
o
Adolescent (13-18 years)
Adults o
Young Adults (19-24 years)
o
Adulthood (25-39 years)
o
Middle-aged Persons (40-59 years)
o
Older People/Old Age (60-84 years)
o
Very Old (85+ years)
By Region •
North America
•
•
•
o
U.S.
o
Canada
o
Mexico
Europe o
Germany
o
France
o
UK
o
Italy
o
Spain
o
Rest of Europe
Asia-Pacific o
Japan
o
China
o
India
o
Australia
o
South Korea
o
Rest of Asia-Pacific
LAMEA o
Brazil
o
South Africa
o
Israel
o
Saudi Arabia
o
Rest of LAMEA
The key companies profiled in the report are Medtronic plc; St. Jude Medical, Inc., Braile Biomedica, Medical Technology Est., Boston Scientific Corporation; Micro Interventional Devices, Inc., Edwards Lifesciences Corporation, LivaNova PLC, JenaValve Technology, Inc., and Cryolife, Inc. Other players operating in this market include Corvia Medical, Inc.,
CardioKinetix, Inc., Biomerics, LLC, Lepu Medical Technology (Beijing) Co., Ltd., XELTIS BV, and Comed B.V. Inquire Here To Buy The Research Report at: https://www.alliedmarketresearch.com/purchase-enquiry/1768
Contact: Shriram Dighe 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States Toll Free: +1-800-792-5285 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1⟨855⟩550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com